"Lupin has emerged as the fastest growing Top 10 Generic player in the markets of Japan, South Africa and the Philippines."
	Mr. Vinod Dhawan President AAMLA & Business Development

Lupin’s focus in the region is on introducing world-class value-added niche products in various therapy areas. Its current basket of offerings comprises products from Anti-TB, Anti-Infectives, Anti-Asthma and Cardiovascular segments. Over the last four-years, Lupin has built a presence in key markets of these regions such as, Australia, UAE, Yemen, Kenya, Kuwait, Lebanon, Peru, Vietnam, Philippines.

Lupin's AAMLA Business division covers the markets of Japan, Australia, South East Asia, Africa, Middle East, and Latin America. It is one of the fastest growing SBUs of the Company.

During 2010, Lupin's business from these markets accounted for 16% of our total consolidated revenues. Ex-India operations along with our subsidiaries Kyowa - Japan, Pharma Dynamics - South Africa and Multicare - Philippines, recorded revenues of INR 7,741 million, a growth of 32% from the previous year. With 67 product filings across various markets, the Company looks forward to further extend its reach into promising new markets and niche segments therein with the introduction of new value added products.

FY 2010 was a year of integration and consolidation in these markets where Lupin focused on creating and achieving synergies between Lupin India and its subsidiaries. The Company started filing DMF's of in-house API's for Japan, sourced 18 new products for the Philippines and negotiated better sourcing rates for its products in South Africa. The division also introduced value added, differentiated and novel products in multiple therapy areas across various countries. These concerted efforts are already resulting in success across key geographies, specifically in advanced markets such as Japan and Australia as well as the emerging markets of South Africa and South East Asia.

Lupin's current formulations business within these markets addresses chronic therapies and lifestyle segments like Cardiovascular, Paediatric, Central Nervous System, Gastro Intestinal and Women's Health as well as Anti-Infectives, Anti-Asthma, and Anti-TB treatments. In a span of four years, our achievements in the AAMLA geographies have already helped build strong foundations for the sustainable future growth of the Company.